CL2016002483A1 - Compuestos derivdos de piridinpirazin-2-carboxamida, moduladores del cb2 proceso de preparacion composicion farmaceutica y su uso para el tratamiento o profilaxis del dolor, dolor neuropátíco, asma, osteoporosis, inflamación, enfermedades psiquiátricas, psicosis, oncología, encefalitis, malaria, alergia, trastornos inmunológicos, artritis reumatoide - Google Patents

Compuestos derivdos de piridinpirazin-2-carboxamida, moduladores del cb2 proceso de preparacion composicion farmaceutica y su uso para el tratamiento o profilaxis del dolor, dolor neuropátíco, asma, osteoporosis, inflamación, enfermedades psiquiátricas, psicosis, oncología, encefalitis, malaria, alergia, trastornos inmunológicos, artritis reumatoide

Info

Publication number
CL2016002483A1
CL2016002483A1 CL2016002483A CL2016002483A CL2016002483A1 CL 2016002483 A1 CL2016002483 A1 CL 2016002483A1 CL 2016002483 A CL2016002483 A CL 2016002483A CL 2016002483 A CL2016002483 A CL 2016002483A CL 2016002483 A1 CL2016002483 A1 CL 2016002483A1
Authority
CL
Chile
Prior art keywords
pain
encephalitis
malaria
oncology
osteoporosis
Prior art date
Application number
CL2016002483A
Other languages
English (en)
Inventor
Luca Gobbi
Uwe Grether
Matthias Nettekoven
Stephan Roever
Mark Rogers-Evans
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CL2016002483A1 publication Critical patent/CL2016002483A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

COMPUESTOS DERIVDOS DE PIRIDINPIRAZIN-2-CARBOXAMIDA, MODULADORES DEL CB2 PROCESO DE PREPARACION COMPOSICION FARMACEUTICA Y SU USO PARA EL TRATAMIENTO O PROFILAXIS DEL DOLOR, DOLOR NEUROPÁTÍCO, ASMA, OSTEOPOROSIS, INFLAMACIÓN, ENFERMEDADES PSIQUIÁTRICAS, PSICOSIS, ONCOLOGÍA, ENCEFALITIS, MALARIA, ALERGIA, TRASTORNOS INMUNOLÓGICOS, ARTRITIS REUMATOIDE
CL2016002483A 2014-04-04 2016-09-30 Compuestos derivdos de piridinpirazin-2-carboxamida, moduladores del cb2 proceso de preparacion composicion farmaceutica y su uso para el tratamiento o profilaxis del dolor, dolor neuropátíco, asma, osteoporosis, inflamación, enfermedades psiquiátricas, psicosis, oncología, encefalitis, malaria, alergia, trastornos inmunológicos, artritis reumatoide CL2016002483A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14163555 2014-04-04

Publications (1)

Publication Number Publication Date
CL2016002483A1 true CL2016002483A1 (es) 2017-03-10

Family

ID=50424143

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016002483A CL2016002483A1 (es) 2014-04-04 2016-09-30 Compuestos derivdos de piridinpirazin-2-carboxamida, moduladores del cb2 proceso de preparacion composicion farmaceutica y su uso para el tratamiento o profilaxis del dolor, dolor neuropátíco, asma, osteoporosis, inflamación, enfermedades psiquiátricas, psicosis, oncología, encefalitis, malaria, alergia, trastornos inmunológicos, artritis reumatoide

Country Status (19)

Country Link
US (2) US20160376262A1 (es)
EP (1) EP3126359A1 (es)
JP (1) JP6654574B2 (es)
KR (1) KR20160142365A (es)
CN (1) CN106132958A (es)
AR (1) AR099933A1 (es)
AU (1) AU2015239539A1 (es)
CA (1) CA2943013A1 (es)
CL (1) CL2016002483A1 (es)
CR (1) CR20160448A (es)
EA (1) EA030116B1 (es)
IL (1) IL247817A0 (es)
MA (1) MA39843A (es)
MX (1) MX2016012689A (es)
PE (1) PE20161370A1 (es)
PH (1) PH12016501865A1 (es)
SG (2) SG10201809066TA (es)
TW (1) TW201623276A (es)
WO (1) WO2015150440A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150135458A (ko) 2013-03-26 2015-12-02 에프. 호프만-라 로슈 아게 신규한 피리딘 유도체
JP6554116B2 (ja) 2014-04-04 2019-07-31 ハー・ルンドベック・アクチエゼルスカベット Ｐｄｅ１阻害剤としてのハロゲン化キナゾリン−ｔｈｆ−アミン
HUE048865T2 (hu) * 2015-12-09 2020-08-28 Hoffmann La Roche Fenilszármazékok 2-es típusú kannabinoid receptor agonistaként
EP3429997A1 (de) 2016-03-16 2019-01-23 Bayer CropScience Aktiengesellschaft N-(cyanbenzyl)-6-(cyclopropylcarbonylamino)-4-(phenyl)-pyridin-2-carboxamid-derivate und verwandte verbindungen als pestizide pflanzenschutzmittel
AR112199A1 (es) 2017-06-20 2019-10-02 Hoffmann La Roche Derivados de piridina como agonistas inversos del receptor cannabinoide 2
JP7454512B2 (ja) 2018-06-27 2024-03-22 エフ． ホフマン－ラ ロシュ アーゲー 優先的カンナビノイド２アゴニストとしてのピリジン及びピラジン誘導体
JP7445610B2 (ja) * 2018-06-27 2024-03-07 エフ． ホフマン－ラ ロシュ アーゲー 医療に有用な新規化合物
CN116640118A (zh) 2018-06-27 2023-08-25 豪夫迈·罗氏有限公司 放射性标记的大麻素受体2配体

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006230292A1 (en) 2005-03-31 2006-10-05 Schering Corporation Spirocyclic thrombin receptor antagonists
FR2887550A1 (fr) 2005-06-24 2006-12-29 Sanofi Aventis Sa Derives de 1-benzylpyrazole-3-acetamide, leur preparation et leur application en therapeutique
PT2155747E (pt) * 2007-05-10 2012-12-19 Ge Healthcare Ltd Imidazol(1,2-a)piridinas e compostos relacionados com actividade nos receptores de canabinóides cb2
EP2311443A1 (en) 2009-10-15 2011-04-20 Rheinische Friedrich-Wilhelms-Universität Pharmaceutical composition containing cannabinoid-receptor 2 antagonists
WO2012031817A1 (en) * 2010-09-09 2012-03-15 F. Hoffmann-La Roche Ag Determination of abca1 protein levels in cells
US9321727B2 (en) * 2011-06-10 2016-04-26 Hoffmann-La Roche Inc. Pyridine derivatives as agonists of the CB2 receptor
US9403808B2 (en) * 2011-10-28 2016-08-02 Hoffmann-La Roche Inc. Pyrazine derivatives
UA116894C2 (uk) * 2012-12-07 2018-05-25 Ф. Хоффманн-Ля Рош Аг Похідні піразину як агоністи канабіноїдного рецептора 2
ES2643058T3 (es) * 2012-12-07 2017-11-21 F. Hoffmann-La Roche Ag Piridina-2-amidas útiles como agonistas de CB2

Also Published As

Publication number Publication date
US20180327396A1 (en) 2018-11-15
US20160376262A1 (en) 2016-12-29
SG11201608108SA (en) 2016-10-28
TW201623276A (zh) 2016-07-01
EP3126359A1 (en) 2017-02-08
MA39843A (fr) 2017-02-08
PH12016501865A1 (en) 2016-12-19
IL247817A0 (en) 2016-11-30
MX2016012689A (es) 2016-12-14
JP2017509676A (ja) 2017-04-06
WO2015150440A1 (en) 2015-10-08
EA030116B1 (ru) 2018-06-29
PE20161370A1 (es) 2016-12-17
AU2015239539A1 (en) 2016-09-29
KR20160142365A (ko) 2016-12-12
EA201691983A1 (ru) 2017-01-30
JP6654574B2 (ja) 2020-02-26
CA2943013A1 (en) 2015-10-08
CR20160448A (es) 2016-12-14
SG10201809066TA (en) 2018-11-29
AR099933A1 (es) 2016-08-31
CN106132958A (zh) 2016-11-16

Similar Documents

Publication Publication Date Title
CL2016002483A1 (es) Compuestos derivdos de piridinpirazin-2-carboxamida, moduladores del cb2 proceso de preparacion composicion farmaceutica y su uso para el tratamiento o profilaxis del dolor, dolor neuropátíco, asma, osteoporosis, inflamación, enfermedades psiquiátricas, psicosis, oncología, encefalitis, malaria, alergia, trastornos inmunológicos, artritis reumatoide
IL258324B (en) Methods to create various cannabis product compounds
ECSP17047155A (es) Productos farmacéuticos y composiciones líquidas estables de anticuerpos contra il-17
PH12017501077A1 (en) Compositions and methods for antibodies targeting bmp6
NZ726859A (en) Synthesis of polycyclic-carbamoylpyridone compounds
EP3361960A4 (en) ADJUSTABLE DEVICES FOR TREATING ARTHRITIS OF THE KNEE
GB201610056D0 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders and osteoarthritis
CL2017000087A1 (es) Un proceso novedoso para la purificación de rhu-gcsf
ITUB20151922A1 (it) Procedimento per la produzione di polietilene tereftalato modificato glicole da materie prime di riciclo
PL3717457T3 (pl) Sposób wytwarzania enzalutamidu z wykorzystaniem nowych związków pośrednich
IN2015CH01182A (es)
PH12016501613A1 (en) Pyrazines modulators of gpr6
GB201610055D0 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders and osteoarthritis
IL312520A (en) Modification of transgenic influenza hemagglutinin polypeptides
IL268550B (en) Purification of pleuromotilin
CL2016002321A1 (es) Compuestos derivados del ácido 2-8-5-cloropirimidin-2-ilamino-6,7,8,9-tetrahidro-5h-pirido3,2-bindol-5-ilacético, moduladores del receptor de prostaglandina d2 composición farmacéutica y su uso para el tratamiento de enfermedadestrastornos alérgicosinmunitarios.
PH12017500499A1 (en) Synthesis of ent-progesterone and intermediates thereof
SI3250535T1 (sl) Postopek za pripravo mnogogliničnega cementa
EP3125931A4 (en) Compositions of multimeric-multiepitope influenza polypeptides and their production
DK3326720T3 (da) Fremgangsmåde til behandling af flerfase mineralske råmaterialer
MY182818A (en) Compositions for the treatment of fibrosis and fibrosis-related conditions
EP3319097A4 (en) High voltage outlet structure of ultra-high voltage shunt reactor
IL263468A (en) New molecules to treat inflammation
EP3494976A4 (en) COMPOSITION FOR PROMOTING THE PRODUCTION OF AN IMMUNOSTIMULATING FACTOR
PL3164110T3 (pl) Kompozycje farmaceutyczne do leczenia łuszczycy